Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy,safety and tolerability in patients with breakthrough cancer pain

Abstract

Background and objectives:

Breakthrough cancer pain (BTcP) affects more than half of patients with cancer pain and has severe detrimental impacts on quality of life (QoL). This study evaluated the efficacy, QoL impact and safety of sublingual fentanyl orally disintegrating tablet (sublingual fentanyl ODT), for the treatment of BTcP in a clinical setting.